NCT06568952

Brief Summary

Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 30, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2024

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

August 20, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 23, 2024

Completed
Last Updated

August 23, 2024

Status Verified

December 1, 2023

Enrollment Period

2 months

First QC Date

August 20, 2024

Last Update Submit

August 22, 2024

Conditions

Pulmonary Hypertension

Outcome Measures

Primary Outcomes (1)

  • tricuspid annular plane systolic excursion

    measurement of tricuspid annular plane systolic excursion by echocardiography

    6 months after carfilzomib treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with multiple myeloma treated with carfilzomib

You may qualify if:

  • Patients treated for multiple myeloma with carfilzomib
  • Patients with echocardiogram before and under treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Simon VALENTIN

Nancy, 54500, France

Location

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Study Officials

  • Simon Valentin, MD

    Université de Lorraine, Département de Pneumologie, CHRU NANCY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 20, 2024

First Posted

August 23, 2024

Study Start

April 30, 2024

Primary Completion

June 30, 2024

Study Completion

July 30, 2024

Last Updated

August 23, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)